DESTINY-Breast03 trial: some questions remain – Authors’ reply

By sjmartinez • May 21, 2023

Hurvitz SA, Curigliano G, Egorov A, Ashfaque S, Cortés J. DESTINY-Breast03 trial: some questions remain - Authors' reply. Lancet. 2023 May 20;401(10389):1653-1654. doi: 10.1016/S0140-6736(23)00681-5. PMID: 37210117.

Tags: Hematology/Oncology, Publications

Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review

Garon EB, Visseren-Grul C, Rizzo MT, Puri T, Chenji S, Reck M. Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small ...

CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity

Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, ...

Clinical Significance of Background Parenchymal Enhancement in Breast Cancer Risk Stratification

Murakami W, Mortazavi S, Yu T, Kathuria-Prakash N, Yan R, Fischer C, McCann KE, Lee-Felker S, Sung. Clinical Significance of Background Parenchymal Enhancement in Breast ...